@aiims_newdelhi @OfficialJipmer @PMOIndia @WHO P(harmacovigilence)MO! https://t.co/YPukLJfAAN https://t.co/Puvol6uD27
RT @edgarvlermamd: SGLT2 inhibitors: Weighing the risks and benefits #AskASN #Nephpearls 👉🏼 https://t.co/mIMxzmHd0L https://t.co/bZe2fvCJ…
RT @edgarvlermamd: SGLT2 inhibitors: Weighing the risks and benefits #AskASN #Nephpearls 👉🏼 https://t.co/mIMxzmHd0L https://t.co/bZe2fvCJ…
RT @edgarvlermamd: SGLT2 inhibitors: Weighing the risks and benefits #AskASN #Nephpearls 👉🏼 https://t.co/mIMxzmHd0L https://t.co/bZe2fvCJ…
RT @edgarvlermamd: SGLT2 inhibitors: Weighing the risks and benefits #AskASN #Nephpearls 👉🏼 https://t.co/mIMxzmHd0L https://t.co/bZe2fvCJ…
SGLT2 inhibitors: Weighing the risks and benefits #AskASN #Nephpearls 👉🏼 https://t.co/mIMxzmHd0L https://t.co/bZe2fvCJSR
RT @edgarvlermamd: SGLT2 inhibitors: Weighing the risks and benefits #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https://t.co/4GaBEjSxi2 https:…
RT @edgarvlermamd: SGLT2 inhibitors: Weighing the risks and benefits #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https://t.co/4GaBEjSxi2 https:…
RT @edgarvlermamd: SGLT2 inhibitors: Weighing the risks and benefits #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https://t.co/4GaBEjSxi2 https:…
RT @edgarvlermamd: SGLT2 inhibitors: Weighing the risks and benefits #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https://t.co/4GaBEjSxi2 https:…
SGLT2 inhibitors: Weighing the risks and benefits #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https://t.co/4GaBEjSxi2 https://t.co/4eqk1YSHJv
RT @DiabetologiaJnl: Use of SGLT2 inhibitors in type 2 diabetes: risks & benefits #T2D https://t.co/7bafPp10Xz https://t.co/WuUbLNv0WN
RT @DiabetologiaJnl: Use of SGLT2 inhibitors in type 2 diabetes: risks & benefits #T2D https://t.co/7bafPp10Xz https://t.co/WuUbLNv0WN
RT @CristobMorales: https://t.co/hSZP5f2Xac Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits (Beatrice C. Lupsa…
RT @CristobMorales: https://t.co/hSZP5f2Xac Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits (Beatrice C. Lupsa…
RT @DiabetologiaJnl: Use of SGLT2 inhibitors in type 2 diabetes: risks & benefits #T2D https://t.co/7bafPp10Xz https://t.co/WuUbLNv0WN
RT @CristobMorales: https://t.co/hSZP5f2Xac Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits (Beatrice C. Lupsa…
RT @DiabetologiaJnl: Use of SGLT2 inhibitors in type 2 diabetes: risks & benefits #T2D https://t.co/7bafPp10Xz https://t.co/WuUbLNv0WN
RT @dr_kevinlee: #SGLT2i class, a case in point, consider risks and benefits. Hence don't just willy-nilly pick it for #t2dm population, th…
RT @DiabetologiaJnl: Use of SGLT2 inhibitors in type 2 diabetes: risks & benefits #T2D https://t.co/7bafPp10Xz https://t.co/WuUbLNv0WN
RT @DiabetologiaJnl: Use of SGLT2 inhibitors in type 2 diabetes: risks & benefits #T2D https://t.co/7bafPp10Xz https://t.co/WuUbLNv0WN
Use of SGLT2 inhibitors in type 2 diabetes: risks & benefits #T2D https://t.co/7bafPp10Xz https://t.co/WuUbLNv0WN
RT @CristobMorales: https://t.co/hSZP5f2Xac Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits (Beatrice C. Lupsa…
I just took time to read this important article about risks and benefits of SGLT2 inhibitors in type 2 diabetes. It's published in the latest collection of @DiabetologiaJnl. https://t.co/iLtH5dnd7n #Diabetes #T2D #T1D
Use of SGLT2 inhibitors in type 2 diabetes: risks and benefits #T2D https://t.co/7bafPpiBP7 https://t.co/kKFilMDxVB
RT @CristobMorales: https://t.co/hSZP5f2Xac Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits (Beatrice C. Lupsa…
RT @CristobMorales: https://t.co/hSZP5f2Xac Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits (Beatrice C. Lupsa…
RT @CristobMorales: https://t.co/hSZP5f2Xac Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits (Beatrice C. Lupsa…
RT @CristobMorales: https://t.co/hSZP5f2Xac Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits (Beatrice C. Lupsa…
RT @CristobMorales: https://t.co/hSZP5f2Xac Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits (Beatrice C. Lupsa…
RT @CristobMorales: https://t.co/hSZP5f2Xac Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits (Beatrice C. Lupsa…
RT @CristobMorales: https://t.co/hSZP5f2Xac Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits (Beatrice C. Lupsa…
https://t.co/hSZP5f2Xac Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits (Beatrice C. Lupsa & Silvio E. Inzucchi) 👏👏👏@DiabetologiaJnl @sociedadSEEN @SEDiabetes @secardiologia @SENefrologia @redGDPS #EASD2018 https://t.co/qZZ
RT @DrJavierCrespo: In addition, SGLT2 inhibitors may be useful in the treatment of some patients with NASH. The future is promising. Revie…
A brief review of #SGLT2 inhibitors, #risks and #benefits 💊⚖️ https://t.co/l9q8TGYP67 https://t.co/Or6fpcRKe4
RT @SemergenGTDM: Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Review article Lupsa BC, et al. Diabetologia…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @ValleAlfonso: @EASDnews Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits 📎https://t.co/7nkrhH7sd9. #GTDiabet…
RT @ValleAlfonso: @EASDnews Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits 📎https://t.co/7nkrhH7sd9. #GTDiabet…
RT @ValleAlfonso: @EASDnews Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits 📎https://t.co/7nkrhH7sd9. #GTDiabet…
RT @ValleAlfonso: @EASDnews Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits 📎https://t.co/7nkrhH7sd9. #GTDiabet…
RT @ValleAlfonso: @EASDnews Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits 📎https://t.co/7nkrhH7sd9. #GTDiabet…
RT @ValleAlfonso: @EASDnews Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits 📎https://t.co/7nkrhH7sd9. #GTDiabet…
RT @ValleAlfonso: @EASDnews Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits 📎https://t.co/7nkrhH7sd9. #GTDiabet…
RT @DrJavierCrespo: In addition, SGLT2 inhibitors may be useful in the treatment of some patients with NASH. The future is promising. Revie…
RT @SemergenGTDM: Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Review article Lupsa BC, et al. Diabetologia…
RT @SemergenGTDM: Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Review article Lupsa BC, et al. Diabetologia…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @DrJavierCrespo: In addition, SGLT2 inhibitors may be useful in the treatment of some patients with NASH. The future is promising. Revie…
RT @SemergenGTDM: Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Review article Lupsa BC, et al. Diabetologia…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @SemergenGTDM: Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Review article Lupsa BC, et al. Diabetologia…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @DrJavierCrespo: In addition, SGLT2 inhibitors may be useful in the treatment of some patients with NASH. The future is promising. Revie…
RT @DrJavierCrespo: In addition, SGLT2 inhibitors may be useful in the treatment of some patients with NASH. The future is promising. Revie…
RT @DrJavierCrespo: In addition, SGLT2 inhibitors may be useful in the treatment of some patients with NASH. The future is promising. Revie…
In addition, SGLT2 inhibitors may be useful in the treatment of some patients with NASH. The future is promising. Review that should also be read by hepatologists. @sepdigestiva @AEEHLiver #NAFLD
RT @SemergenGTDM: Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Review article Lupsa BC, et al. Diabetologia…
RT @SemergenGTDM: Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Review article Lupsa BC, et al. Diabetologia…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @SemergenGTDM: Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Review article Lupsa BC, et al. Diabetologia…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @SemergenGTDM: Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Review article Lupsa BC, et al. Diabetologia…
RT @SemergenGTDM: Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Review article Lupsa BC, et al. Diabetologia…
RT @SemergenGTDM: Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Review article Lupsa BC, et al. Diabetologia…
RT @SemergenGTDM: Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Review article Lupsa BC, et al. Diabetologia…
RT @SemergenGTDM: Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Review article Lupsa BC, et al. Diabetologia…
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Review article Lupsa BC, et al. Diabetologia. 2018. https://t.co/m16aDpDUSS https://t.co/G9C4AQhFHf
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review https://t.co/A7NYTls42B … #ESCCongresspic.twitter.com/ywBaHMINsF https://t.co/uD70gTrGbH https://t.co/6sGHAXlunV
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…
RT @cristinatejerap: Use of iSGLT2 in #diabetes type 2: weighing the risks and benefits. Excellent review ▶️ https://t.co/WBSpSiBvv1 #ESCCo…